RxDoctor Payments Data

Alexander Bie, MD

Family Medicine · Miami, FLNPI 1114549318

Payments from drug & device makers

$485in general payments, 2019–2025

Across 15 payments — averaging $32.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$147
  • AbbVie$119
  • Medtronic$91
  • Novo Nordisk$43
  • Lilly USA, LLC$29
  • E.r. Squibb & Sons, L.L.C.$22
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$485 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$83,975
Medicare patients
363
Services billed
768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$55,113
OzempicSemaglutide37$43,100
JardianceEmpagliflozin18$30,484
ProliaDenosumab13$22,735
MounjaroTirzepatide17$17,355
XareltoRivaroxaban17$14,478
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$12,961
MyrbetriqMirabegron19$11,359
LinzessLinaclotide12$11,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,129
Celecoxib18$4,482
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,444
Rosuvastatin Calcium270$2,400
Albuterol Sulfate HfaAlbuterol Sulfate92$2,230
Atorvastatin Calcium253$2,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$43,10037 claims
AmgenProlia$20$22,73513 claims
Lilly USA, LLCMounjaro$29$17,35517 claims
AstraZenecaBreztri Aerosphere$147$12,96116 claims
AbbVieLinzess$119$11,07412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →